Stephen Hermitage Appointed Vice President of CMC Operations of Sai Life Sciences

MANCHESTER, England and HYDERABADInde, November 23, 2022 /PRNewswire/ — Sai Life Sciences, une global contract research, development and manufacturing organization (CRO-CDMO) leaders, today announced the appointment of Stephen Hermitage (Steve) as Vice President of CMC Operations. As such, Steve Hermitage will join Sai Life Sciences’ global R&D leadership team, to which he will bring his deep experience in process development and drug discovery.

During this advert, Sauri Gudlavalleti, COO, said: “Over the past few years, our team has established a formidable reputation as a high-quality scientific unit capable of solving complex challenges in chemistry. I am delighted to welcome Steve, a seasoned pharmaceutical industry expert, to Sai Life Sciences. His addition to our global service delivery team reinforces our ongoing efforts to build strong partnerships with customers and exceed their expectations by raising the bar for innovation, speed and efficiency. .

Steve Hermitage joins Sai Life Sciences from GlaxoSmithKline (GSK), where he was a department head and member of the global chemical development leadership team. During his 24 years at GSK, Steve Hermitage has worked successfully with numerous project managers and their teams to deliver the APIs and regulatory applications that facilitate preclinical and clinical activities throughout the development lifecycle – from Pragmatic accelerated early-stage sourcing to complex Quality Control by Design (QbD) strategies that support the business case and go-to-market. Throughout his career at GSK, Steve Hermitage has gained extensive professional experience in pharmaceutical outsourcing in indiaChina and Europenotably at the head of the technical outsourcing group in the context of chemical development.

Regarding the appointment of Steve Hermitage, Dean Edneyinternational director of R&D processes said, “Steve will bring best practices in late-stage chemical and API development for the Manchester and Hyberabad programs. His experience will also give us new perspectives on project and program management, which will enable us to continue to strive for excellence in partnering with clients. »

Steve Hermitage holds a BA and MA from Oxford University, a PhD from the University of Liverpool and he conducted his postdoctoral studies at the University of Cambridge. He is a Fellow of the Royal Society of Chemistry and a Chartered Chemist (FRSC CChem).

About his nomination, Steve Hermitage said, “I am incredibly excited to join Sai Life Sciences at a time when the business is transforming. Each of my interactions with my colleagues in the company has allowed me to observe a real collective ambition to build a leading organization that delivers projects to customers based on sound science combined with efficient manufacturing capability. while maintaining high standards of safety and quality. »

About Sai Life Sciences

Sai Life Sciences is a CRO-CDMO organization integrating all services which works with innovative pharmaceutical and biotechnology companies around the world to accelerate the discovery, development and manufacturing of complex small molecules. The company has over 2,200 employees across its locations in India, UK and USA. Sai Life Sciences is a private company backed by international investors TPG Capital and HBM Healthcare Investments.


SOURCE Sai Life Sciences